CXCL16 in Vascular Pathology Research: from Macro Effects to microRNAs.

Chemokines and their receptors have become significant factors in atherosclerosis research. CXCL16 is a multifunctional agent located on a separate locus to all other known chemokines and binds only to its "unique" receptor named CXCR6. As a scavenger receptor, adhesion molecule, and chemokine, it quickly became an interesting target in atherosclerosis research as all its functions have a role in vascular pathology. The investigation of the role of CXCL16 in atherosclerosis, although shown in in vitro studies, animal knockout models, and CXCL16 gene polymorphisms, haplotypes, and circulating levels, still shows puzzling results. Genetic and epigenetic studies have just scratched the surface of research necessary for a better assessment of the significance and perspective of this marker in plaque development and progression. In this review, we will summarize current knowledge about CXCL16 in atherosclerosis. Additionally, we will point out the importance of bioinformatics tools for the detection of potentially new CXCL16 regulatory networks through microRNA activity. This review aims to provide a better understanding of the underlying mechanisms, define more specific biomarkers, and discover new therapeutic targets.

[1]  A. Schober,et al.  MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis , 2015, Nature Reviews Cardiology.

[2]  T. Akasaka,et al.  MicroRNAs and Cardiovascular Diseases , 2015, BioMed research international.

[3]  N. Veljkovic,et al.  CXCL16 haplotypes in patients with human carotid atherosclerosis: preliminary results. , 2015, Journal of atherosclerosis and thrombosis.

[4]  J. Fish,et al.  Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation , 2014, Front. Genet..

[5]  A. Davies,et al.  MicroRNAs in Atherosclerosis , 2014, Journal of Vascular Research.

[6]  L. Lerman,et al.  The Association between Circulating MicroRNA Levels and Coronary Endothelial Function , 2014, PloS one.

[7]  Zhi-Hong Liu,et al.  Increased levels of plasma CXC-Chemokine Ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension. , 2014, Heart & lung : the journal of critical care.

[8]  Jasmina M. Jovanovic,et al.  The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. , 2014, Medical hypotheses.

[9]  E. van Rooij,et al.  Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury , 2014, Cardiovascular research.

[10]  Lei Zhang,et al.  Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases , 2014, Scientific Reports.

[11]  T. Kara,et al.  MicroRNAs Involved in the Lipid Metabolism and Their Possible Implications for Atherosclerosis Development and Treatment , 2014, Mediators of inflammation.

[12]  Aijun Ma,et al.  Elevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke , 2014, Archives of medical science : AMS.

[13]  S. Boulkroun,et al.  Inhibition of MicroRNA-92a Prevents Endothelial Dysfunction and Atherosclerosis in Mice , 2014, Circulation research.

[14]  Takeshi Kimura,et al.  MicroRNAs and Lipoprotein Metabolism. , 2014, Journal of atherosclerosis and thrombosis.

[15]  Michelangelo Ceci,et al.  Integrating microRNA target predictions for the discovery of gene regulatory networks: a semi-supervised ensemble learning approach , 2014, BMC Bioinformatics.

[16]  Xinghui Sun,et al.  Endothelial MicroRNAs and Atherosclerosis , 2013, Current Atherosclerosis Reports.

[17]  N. Hacohen,et al.  The scavenger receptor SCARF1 mediates apoptotic cell clearance and prevents autoimmunity , 2013, Nature Immunology.

[18]  D. Tollervey,et al.  Mapping the Human miRNA Interactome by CLASH Reveals Frequent Noncanonical Binding , 2013, Cell.

[19]  J. Herlitz,et al.  Multimarker Risk Assessment Including Osteoprotegerin and CXCL16 in Acute Coronary Syndromes , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[20]  Sergios Gatidis,et al.  The Inflammatory Chemokine CXC Motif Ligand 16 Triggers Platelet Activation and Adhesion Via CXC Motif Receptor 6–Dependent Phosphatidylinositide 3-Kinase/Akt Signaling , 2012, Circulation research.

[21]  G. Vilahur,et al.  Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease , 2012, European heart journal. Acute cardiovascular care.

[22]  B. Xiao,et al.  Role of microRNAs in endothelial inflammation and senescence , 2012, Molecular Biology Reports.

[23]  P. Fisher,et al.  Multifunction Protein Staphylococcal Nuclease Domain Containing 1 (SND1) Promotes Tumor Angiogenesis in Human Hepatocellular Carcinoma through Novel Pathway That Involves Nuclear Factor κB and miR-221* , 2012, The Journal of Biological Chemistry.

[24]  Robert H. Jenkins,et al.  Post-Transcriptional Regulation of Transforming Growth Factor Beta-1 by MicroRNA-744 , 2011, PloS one.

[25]  H. Robenek,et al.  SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion. , 2011, Atherosclerosis.

[26]  J. Kooner,et al.  The CXCL16 A181V Mutation Selectively Inhibits Monocyte Adhesion to CXCR6 but Is Not Associated With Human Coronary Heart Disease , 2011, Arteriosclerosis, Thrombosis and Vascular Biology.

[27]  I. Jurisica,et al.  NAViGaTing the Micronome – Using Multiple MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAs , 2011, PloS one.

[28]  E. Izaurralde,et al.  Gene silencing by microRNAs: contributions of translational repression and mRNA decay , 2011, Nature Reviews Genetics.

[29]  Ana Kozomara,et al.  miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..

[30]  J. Su,et al.  Chemokine CXC Ligand 16 serum concentration but not A181V genotype is associated with atherosclerotic stroke. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[31]  Stefanie Dimmeler,et al.  Circulating MicroRNAs in Patients With Coronary Artery Disease , 2010, Circulation research.

[32]  G. Adema,et al.  An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells , 2010, Journal of leukocyte biology.

[33]  C. Speyer,et al.  Regulation of the Expression and Activity of the Antiangiogenic Homeobox Gene GAX/MEOX2 by ZEB2 and MicroRNA-221 , 2010, Molecular and Cellular Biology.

[34]  Yaling Han,et al.  An intron polymorphism in the CXCL16 gene is associated with increased risk of coronary artery disease in Chinese Han population: a large angiography-based study. , 2010, Atherosclerosis.

[35]  K. Vickers,et al.  MicroRNAs in atherosclerosis and lipoprotein metabolism , 2010, Current opinion in endocrinology, diabetes, and obesity.

[36]  G. Christensen,et al.  Increased Production of CXCL16 in Experimental and Clinical Heart Failure: A Possible Role in Extracellular Matrix Remodeling , 2009, Circulation. Heart failure.

[37]  T. Kita,et al.  Circulating soluble SR-PSOX/CXCL16 as a biomarker for acute coronary syndrome -comparison with high-sensitivity C-reactive protein. , 2009, Journal of atherosclerosis and thrombosis.

[38]  Nectarios Koziris,et al.  Accurate microRNA target prediction correlates with protein repression levels , 2009, BMC Bioinformatics.

[39]  I. Tabas.  Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. , 2009, Antioxidants & redox signaling.

[40]  T. Omland,et al.  Soluble CXCL16 Predicts Long-Term Mortality in Acute Coronary Syndromes , 2009, Circulation.

[41]  V. Kim,et al.  Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.

[42]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[43]  Y. Rui,et al.  Lentiviral vector-mediated siRNA knockdown of SR-PSOX inhibits foam cell formation in vitro , 2008, Acta Pharmacologica Sinica.

[44]  Y. Sheikine,et al.  CXCL16/SR-PSOX--a friend or a foe in atherosclerosis? , 2008, Atherosclerosis.

[45]  Michael Kertesz,et al.  The role of site accessibility in microRNA target recognition , 2007, Nature Genetics.

[46]  P. Murphy,et al.  Chemokine regulation of atherosclerosis , 2007, Journal of leukocyte biology.

[47]  C. Weber,et al.  Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by α- and γ-secretases , 2007 .

[48]  C. Weber,et al.  Regulated Shedding of Transmembrane Chemokines by the Disintegrin and Metalloproteinase 10 Facilitates Detachment of Adherent Leukocytes1 , 2007, The Journal of Immunology.

[49]  P. V. van Riel,et al.  Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis. , 2007, Biochemical and biophysical research communications.

[50]  K. Ley,et al.  CXCR6 Promotes Atherosclerosis by Supporting T-Cell Homing, Interferon-&ggr; Production, and Macrophage Accumulation in the Aortic Wall , 2007, Circulation.

[51]  U. Dietrich,et al.  Application of the EIIP/ISM bioinformatics concept in development of new drugs. , 2007, Current medicinal chemistry.

[52]  M. Reilly,et al.  CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. , 2007, Journal of the American College of Cardiology.

[53]  Laura Mariani,et al.  MicroRNAs modulate the angiogenic properties of HUVECs. , 2006, Blood.

[54]  A. Hamsten,et al.  Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. , 2006, Atherosclerosis.

[55]  Yvonne Tay,et al.  A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes , 2006, Cell.

[56]  I. Charo,et al.  Targeted Disruption of the Scavenger Receptor and Chemokine CXCL16 Accelerates Atherosclerosis , 2006, Circulation.

[57]  L. Badimón,et al.  Cell biology and lipoproteins in atherosclerosis. , 2006, Current molecular medicine.

[58]  T. V. van Berkel,et al.  Scavenger receptors: friend or foe in atherosclerosis? , 2005, Current opinion in lipidology.

[59]  Aloke V. Finn,et al.  Atherosclerotic Plaque Progression and Vulnerability to Rupture: Angiogenesis as a Source of Intraplaque Hemorrhage , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[60]  T. Kita,et al.  CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. , 2005, Biochemical and biophysical research communications.

[61]  Kristin C. Gunsalus,et al.  microRNA Target Predictions across Seven Drosophila Species and Comparison to Mammalian Targets , 2005, PLoS Comput. Biol..

[62]  A. Hamsten,et al.  Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR‐PSOX gene , 2005, Journal of internal medicine.

[63]  N. Kadowaki,et al.  Distribution and kinetics of SR‐PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells , 2005, Journal of leukocyte biology.

[64]  Xinghua Zhou,et al.  IL-18 Accelerates Atherosclerosis Accompanied by Elevation of IFN-&ggr; and CXCL16 Expression Independently of T Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[65]  Mitchell Kronenberg,et al.  Intravascular Immune Surveillance by CXCR6+ NKT Cells Patrolling Liver Sinusoids , 2005, PLoS biology.

[66]  M. Lambert,et al.  Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. , 2005, Combinatorial chemistry & high throughput screening.

[67]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[68]  E. Butcher,et al.  Role for CXCR6 in Recruitment of Activated CD8+ Lymphocytes to Inflamed Liver1 , 2005, The Journal of Immunology.

[69]  L. Norgren,et al.  The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. , 2004, Biochemical and biophysical research communications.

[70]  M. Cybulsky,et al.  Leukocyte recruitment to atherosclerotic lesions. , 2004, The Canadian journal of cardiology.

[71]  S. Rose-John,et al.  The Transmembrane CXC-Chemokine Ligand 16 Is Induced by IFN-γ and TNF-α and Shed by the Activity of the Disintegrin-Like Metalloproteinase ADAM10 1 , 2004, The Journal of Immunology.

[72]  Francisco E. Baralle,et al.  Genomic variants in exons and introns: identifying the splicing spoilers , 2004, Nature Reviews Genetics.

[73]  U. Hedin,et al.  CXCL16/SR-PSOX Is an Interferon-&ggr;–Regulated Chemokine and Scavenger Receptor Expressed in Atherosclerotic Lesions , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[74]  P. Dempsey,et al.  A Disintegrin and Metalloproteinase 10-Mediated Cleavage and Shedding Regulates the Cell Surface Expression of CXC Chemokine Ligand 16 , 2004, The Journal of Immunology.

[75]  T. Kita,et al.  Cell surface‐anchored SR‐PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6‐expressing cells , 2004, Journal of leukocyte biology.

[76]  B. Chandrasekar,et al.  CXCL16 Signals via Gi, Phosphatidylinositol 3-Kinase, Akt, IκB Kinase, and Nuclear Factor-κB and Induces Cell-Cell Adhesion and Aortic Smooth Muscle Cell Proliferation* , 2004, Journal of Biological Chemistry.

[77]  Osamu Yoshie,et al.  Cutting Edge: Profile of Chemokine Receptor Expression on Human Plasma Cells Accounts for Their Efficient Recruitment to Target Tissues 1 , 2003, The Journal of Immunology.

[78]  H. Robenek,et al.  Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[79]  P. Groot,et al.  Fractalkine Is Expressed by Smooth Muscle Cells in Response to IFN-γ and TNF-α and Is Modulated by Metalloproteinase Activity1 , 2002, The Journal of Immunology.

[80]  Masashi Komeda,et al.  Expression of SR-PSOX, a Novel Cell-Surface Scavenger Receptor for Phosphatidylserine and Oxidized LDL in Human Atherosclerotic Lesions , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[81]  D. Soler,et al.  Expression Cloning of the STRL33/BONZO/TYMSTR Ligand Reveals Elements of CC, CXC, and CX3C Chemokines , 2001, The Journal of Immunology.

[82]  E. Kunkel,et al.  Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. , 2001, The Journal of clinical investigation.

[83]  T. Kita,et al.  Molecular Cloning of a Novel Scavenger Receptor for Oxidized Low Density Lipoprotein, SR-PSOX, on Macrophages* , 2000, The Journal of Biological Chemistry.

[84]  A. Daugherty,et al.  Exogenous interferon-γ enhances atherosclerosis in apolipoprotein E-/- mice , 2000 .

[85]  Sharon Engel,et al.  A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo , 2000, Nature Immunology.

[86]  E. Butcher,et al.  The Primate Lentiviral Receptor Bonzo/STRL33 Is Coordinately Regulated with CCR5 and Its Expression Pattern Is Conserved Between Human and Mouse1 , 2000, The Journal of Immunology.

[87]  K. Moores,et al.  Fractalkine Cleavage from Neuronal Membranes Represents an Acute Event in the Inflammatory Response to Excitotoxic Brain Damage , 2000, The Journal of Neuroscience.

[88]  R. Steinman,et al.  Short Communication: The Immunodeficiency Virus Coreceptor, Bonzo/STRL33/TYMSTR, Is Expressed by Macaque and Human Skin- and Blood-Derived Dendritic Cells , 2000 .

[89]  R. Doms,et al.  Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. , 2000, Blood.

[90]  P. Slocombe,et al.  The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 , 2000, FEBS letters.

[91]  S. Goda,et al.  CX3C-Chemokine, Fractalkine-Enhanced Adhesion of THP-1 Cells to Endothelial Cells Through Integrin-Dependent and -Independent Mechanisms1 , 2000, The Journal of Immunology.

[92]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[93]  J. Westwick,et al.  Chemokines and T lymphocytes: more than an attraction. , 1998, Immunity.

[94]  D. Housman,et al.  Cloning and chromosomal mapping of an orphan chemokine receptor: mouse RDC1 , 1998, Immunogenetics.

[95]  J L Witztum,et al.  Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. , 1997, The Journal of clinical investigation.

[96]  D. Littman,et al.  Expression cloning of new receptors used by simian and human immunodeficiency viruses , 1997, Nature.

[97]  J. Gutiérrez-Ramos,et al.  Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation , 1997, Nature.

[98]  K. Peden,et al.  STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.

[99]  A. Tall,et al.  IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. , 1997, The Journal of clinical investigation.

[100]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[101]  A. B. Kay,et al.  Lymphocytes , 1991 .

[102]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[103]  Yongjian Wu,et al.  MicroRNAs: important modulators of oxLDL-mediated signaling in atherosclerosis. , 2013, Journal of atherosclerosis and thrombosis.

[104]  D. Atar,et al.  Soluble CXCL16 and long-term outcome in acute ischemic stroke. , 2012, Atherosclerosis.

[105]  Chunxiang Zhang,et al.  Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. , 2012, Journal of molecular and cellular cardiology.

[106]  T. Kudo,et al.  Angiogenesis in atherosclerotic plaque obtained from carotid endarterectomy: association between symptomatology and plaque morphology. , 2010, Neurologia medico-chirurgica.

[107]  G. Hansson,et al.  Chemokines as potential therapeutic targets in atherosclerosis. , 2006, Current drug targets.

[108]  B. Chandrasekar,et al.  CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. , 2004, The Journal of biological chemistry.

[109]  K. Ley,et al.  Expression of CXCL16 in human T cells. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[110]  Anton J. Enright,et al.  MicroRNA Targets in Drosophila , 2003, Genome Biology.

[111]  P. Groot,et al.  Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. , 2002, Journal of immunology.

[112]  A. Daugherty,et al.  Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. , 2000, The American journal of pathology.

[113]  R. Steinman,et al.  The immunodeficiency virus coreceptor, Bonzo/STRL33/TYMSTR, is expressed by macaque and human skin- and blood-derived dendritic cells. , 2000, AIDS research and human retroviruses.

[114]  A. Zlotnik,et al.  Recent advances in chemokines and chemokine receptors. , 1999, Critical reviews in immunology.

[115]  M. Freeman.  Scavenger receptors in atherosclerosis , 1997, Current opinion in hematology.

[116]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[117]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[118]  M. Brown,et al.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. , 1979, Proceedings of the National Academy of Sciences of the United States of America.